September 5, 2022
September 5, 2022

The progress of the Injectafer claim in the US

Pogust Goodhead continues to fight for individuals who have been injured by the iron deficiency anemia drug, Injectafer.

Injectafer was brought to the US market in 2013 and remains on the market today.

Injectafer is generally used in adult patients who have an intolerance or unsatisfactory response to oral iron supplements.  A healthcare professional injects the drug intravenously, often in two doses, approximately seven days apart.  Each dose is typically 750 mg, for a total cumulative dose of 1500 mg of iron, per course.

Injectafer can cause patients to experience renal phosphate wasting, which is when an individual excretes phosphorous through the urine.  This form of hypophosphatemia causes injuries such as fatigue, weakness, bone pain, joint pain, neuralgias, myalgias, tachycardia/heart dysfunction, altered mental state, seizures, numbness and tooth decay.  In serious cases, patients can experience osteomalacia, osteopenia, and rhabdomyolysis.

Meanwhile, there are multiple other IV iron drugs on the market that do not cause this side effect.

Despite all of the medical studies demonstrating the disproportionate rates of severe and extreme hypophosphatemia among Injectafer users, prior to February 2020, the Injectafer label did not mention severe or symptomatic hypophosphatemia as a potential risk of using the drug.

Prior to February 2020, there was no information about hypophosphatemia in the warnings and precautions section of the label.  Additionally, the label change in February 2020 merely warned prescribers about monitoring serum phosphate levels in patients at risk for low serum phosphate who require a repeated course of treatment.

To date, the Injectafer label fails to properly or adequately warn about the significant dangers that patients can experience with Injectafer-induced hypophosphatemia. Thus, medical providers were never made aware (and still are not aware) of the serious implications of severe and/or symptomatic hypophosphatemia caused by Injectafer.

In November 2018, we were the first law firm in the entire country to file a lawsuit against the Manufacturers and Distributors of Injectafer as a result of hypophosphatemia.

Today, three and a half years later, we have filed over 125 lawsuits on behalf of clients that were seriously injured as a result of the Defendants’ Injectafer product.

We have been at the forefront of this litigation, working directly with another leading mass tort firm, Robins Kaplan LLP.

Since filing the first Injectafer complaint, our litigation team has conducted extensive discovery, including depositions of corporate representatives and review of millions of pages of Defendants’ records.  We have worked tirelessly to build a liability theory against the Defendants, which proves that they were aware of the potential for Injectafer-induced hypophosphatemia before the drug was made available to the public.

Despite affirmative knowledge of the dangers of Injectafer and hypophosphatemia, the Defendants actively ignored it and failed to conduct proper clinical trials or warn about the symptoms secondary to Injectafer-induced hypophosphatemia.

Today, our firm is still litigating and pursuing claims against the manufacturers and distributors of Injectafer in both State and Federal Court.

We have exchanged expert reports and are scheduled to start jury trials in late 2022 / early 2023.  We are doing everything in our power to hold the Defendants responsible for the harm that Injectafer has caused, while simultaneously attempting to educate the medical community and patients on the danger of hypophosphatemia.

We will continue to fight for our clients until these goals have been reached.

You can join the claim via our website today.

More Opinions

Jan Faulkner: 'Why I’m launching a campaign to extend the limitation period on medical devices'
Pogust Goodhead's Client Liason Officer Jan Faulkner has launched a campaign called 'Raise the Limit' to extend the medical limitation period.
Read More
New guidelines balance the twin interests of promoting competition and protecting the environment 
The Competition and Markets Authority recently published guidance to help businesses understand how they can lawfully collaborate on environmental sustainability...
Read More
Re-analysis of puberty blockers study raises concerns about mental health in transgender youth
In 2011, a study initially found that hormone blockers made 'no change' to psychological function, but a reanalysis of the data showed that 34% of participants...
Read More